Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$59.92
+0.9%
$67.08
$25.98
$110.25
$6.28B0.722.70 million shs334,829 shs
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$119.46
+1.1%
$120.38
$87.14
$127.57
$6.80B0.95269,000 shs49,046 shs
HealthEquity, Inc. stock logo
HQY
HealthEquity
$75.26
-2.0%
$80.20
$54.09
$84.49
$6.46B0.55590,840 shs288,387 shs
PACS
PACS Group
$27.50
+2.2%
$0.00
$22.61
$27.93
$4.13BN/A564,946 shs129,965 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
+2.54%-9.07%-17.05%-22.41%+52.40%
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
+0.34%+0.16%-0.96%-2.07%+28.37%
HealthEquity, Inc. stock logo
HQY
HealthEquity
-0.70%-4.43%-3.79%-4.37%+35.60%
PACS
PACS Group
+7.34%+7.72%+12.17%+2,691,999,900.00%+2,691,999,900.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
4.2834 of 5 stars
4.42.00.04.61.80.80.6
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
4.1803 of 5 stars
1.40.03.34.83.42.52.5
HealthEquity, Inc. stock logo
HQY
HealthEquity
4.5815 of 5 stars
4.53.00.00.02.92.53.1
PACS
PACS Group
3.0493 of 5 stars
3.50.00.00.02.81.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
2.87
Moderate Buy$81.6036.18% Upside
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
2.80
Moderate Buy$124.604.30% Upside
HealthEquity, Inc. stock logo
HQY
HealthEquity
3.00
Buy$96.1727.78% Upside
PACS
PACS Group
3.00
Buy$30.5010.91% Upside

Current Analyst Ratings

Latest ENSG, PACS, HQY, and CYTK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2024
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$94.00
5/14/2024
PACS
PACS Group
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$31.00
5/9/2024
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetMarket Outperform ➝ Market Outperform$110.00 ➝ $106.00
5/9/2024
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$107.00 ➝ $106.00
5/9/2024
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$108.00
5/8/2024
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$94.00
5/6/2024
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$130.00 ➝ $135.00
5/6/2024
PACS
PACS Group
Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$31.00
5/6/2024
PACS
PACS Group
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$27.00
5/6/2024
PACS
PACS Group
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$32.00
5/6/2024
PACS
PACS Group
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$31.00
(Data available from 5/15/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
$7.53M834.34N/AN/A($3.78) per share-15.85
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$3.73B1.82$5.83 per share20.49$27.82 per share4.29
HealthEquity, Inc. stock logo
HQY
HealthEquity
$999.59M6.46$3.33 per share22.62$23.72 per share3.17
PACS
PACS Group
$3.11B1.33N/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$526.24M-$5.40N/AN/AN/A-14,141.74%N/A-67.32%8/1/2024 (Estimated)
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$209.40M$3.8031.4421.841.585.67%17.60%6.33%7/25/2024 (Estimated)
HealthEquity, Inc. stock logo
HQY
HealthEquity
$55.71M$0.64117.5926.971.265.57%6.91%4.41%6/3/2024 (Confirmed)
PACS
PACS Group
N/AN/A0.0014.78N/AN/AN/AN/A8/12/2024 (Estimated)

Latest ENSG, PACS, HQY, and CYTK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/3/2024N/A
HealthEquity, Inc. stock logo
HQY
HealthEquity
$0.6620N/A-$0.6620N/AN/AN/A  
5/8/2024Q1 2024
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.16-$1.33-$0.17-$1.33$0.91 million$0.84 million    
3/19/2024Q4 2024
HealthEquity, Inc. stock logo
HQY
HealthEquity
$0.42$0.50+$0.08$0.70$258.56 million$262.39 million
2/27/2024Q4 2023
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
-$1.03-$1.38-$0.35-$1.38$7.62 million$1.70 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/AN/AN/AN/AN/A
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
$0.240.20%+4.71%6.32%17 Years
HealthEquity, Inc. stock logo
HQY
HealthEquity
N/AN/AN/AN/AN/A
PACS
PACS Group
N/AN/AN/AN/AN/A

Latest ENSG, PACS, HQY, and CYTK Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/22/2024
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
Quarterly$0.060.19%3/27/20243/31/20244/30/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
7.19
6.12
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
0.09
1.53
1.53
HealthEquity, Inc. stock logo
HQY
HealthEquity
0.43
4.76
4.76
PACS
PACS Group
N/AN/AN/A

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
N/A
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
96.12%
HealthEquity, Inc. stock logo
HQY
HealthEquity
99.55%
PACS
PACS Group
N/A

Insider Ownership

CompanyInsider Ownership
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
3.40%
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
3.90%
HealthEquity, Inc. stock logo
HQY
HealthEquity
2.70%
PACS
PACS Group
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Cytokinetics, Incorporated stock logo
CYTK
Cytokinetics
423104.85 million99.50 millionOptionable
The Ensign Group, Inc. stock logo
ENSG
The Ensign Group
35,30056.92 million54.70 millionOptionable
HealthEquity, Inc. stock logo
HQY
HealthEquity
3,15085.80 million83.48 millionOptionable
PACS
PACS Group
32,433150.15 millionN/AOptionable

ENSG, PACS, HQY, and CYTK Headlines

Recent News About These Companies

Why Hindu groups are up in arms against Democratic think tank in US
PACS Group, Inc.'s (NYSE:PACS) Quiet Period To Expire on May 21st
PACS Group, Inc. Reports First Quarter 2024 Results
PACS Group (PACS) Set to Announce Earnings on Monday

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Cytokinetics logo

Cytokinetics

NASDAQ:CYTK
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
The Ensign Group logo

The Ensign Group

NASDAQ:ENSG
The Ensign Group, Inc. provides skilled nursing, senior living, and rehabilitative services. It operates through two segments: Skilled Services and Standard Bearer. The company's Skilled Services segment engages in the operation of skilled nursing facilities and rehabilitation therapy services for patients with chronic conditions, prolonged illness, and the elderly; and offers nursing facilities including specialty care, such as on-site dialysis, ventilator care, cardiac, and pulmonary management, as well as standard services comprising room and board, special nutritional programs, social services, recreational activities, entertainment, and other services. Its Standard Bearer segment is comprised of selected real estate properties owned by Standard Bearer and leased to skilled nursing and senior living operators. In addition, the company provides ancillary services consisting of digital x-ray, ultrasound, electrocardiograms, sub-acute services, dialysis, respiratory, and long-term care pharmacy and patient transportation to people in their homes or at long-term care facilities, as well as mobile diagnostics. It operates in Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington and Wisconsin. The company was incorporated in 1999 and is based in San Juan Capistrano, California.
HealthEquity logo

HealthEquity

NASDAQ:HQY
HealthEquity, Inc. provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. It also provides investment platform; and online-only automated investment advisory services through Advisor, a Web-based tool. In addition, the company offers flexible spending accounts; health reimbursement arrangements; and Consolidated Omnibus Budget Reconciliation Act continuation services, as well as administers pre-tax commuter benefit programs. It serves clients through a direct sales force; benefits brokers and advisors; and a network of health plans, benefits administrators, benefits brokers and consultants, and retirement plan record-keepers. HealthEquity, Inc. was incorporated in 2002 and is based in Draper, Utah.

PACS Group

NYSE:PACS
PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.